on MedMira, Inc. (CVE:MIR)
Health Canada Grants Approval for MedMira's Rapid Syphilis Test
MedMira Inc. has obtained approval from Health Canada for its Reveal® TP Antibody Test, the fastest standalone syphilis screening tool available in Canada. This advancement is crucial for expanding syphilis testing, especially in the Prairie provinces where the infection rates are climbing. The test provides immediate results from a finger-prick sample, utilizing MedMira's Rapid Vertical Flow Technology.
The approval followed extensive clinical trials, including a study led by Dr. Stuart Skinner and Nikki Williamson. The trials spanned multiple sites in Alberta and Saskatchewan, reflecting a collaboration among healthcare professionals and community agencies. Reveal® TP can be used in diverse settings, enhancing syphilis diagnosis access across Canada.
Canada has seen an increase in syphilis and congenital syphilis cases, prompting healthcare officials to term it a public health emergency. MedMira's test offers a significant step toward addressing this crisis by aiding in early detection and connection to care.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MedMira, Inc. news